You are an absolute moron. Let me address your 3 points here.
1 - Zelnorm - was not removed due to CV's with women of child bearing age, this happened in elderly patients. Since you sell Amitiza currently, you would know that 95% of docs felt it was BS that Zelnorm was removed in the way that it was.
2 - Pregnancy Cat C, really? You think this means anything? Nobody is suggesting that we will be targeting actual pregnant women for this drug. Millions of women of child bearing age (that is old enough to be pregnant, but not actually pregnant-in case you don't understand what that means) are currently on SSRI therapy, just one example. Here's the big difference between these SSRI's, Linzess and Amitiza. The label for Amitiza states a woman of child bearing age must have a negative pregnancy test and be monitored on contraceptive therapy while on Amitiza. Amitiza is a derivative of a prostaglandin, same one as misoprostol actually. Learn your science, you will then understand why prostaglandins are abortion pills. Okay, get it?
3 - About you not getting the job at Ironwood. Please tell us the feedback you were given from the recruiters, or did you actually make it to a face-to-face with management? I'm really curious the reasons on why they didn't send you on? Could be your business acumen?
4 - Here's a bonus. Since you are the OP of this thread, here's the difference between Ironwood and Takeda. Ironwood will ethically address the boxed warning for peds. Takeda swept under the rug the issue that Amitiza is a derivative of the same prostaglandin that misoprostol is from. Fortunately, there were many Novartis reps in the field that were able to consult the docs about this. Since Linzess is a IBS drug, you will see the patient population that will be targeted are these women of child bearing age (not peds, and remind you those women must take a preg test and be monitored on contraceptive therapy while on Amitiza).